{
    "clinical_study": {
        "@rank": "16689", 
        "acronym": "GTCA", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles."
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo  from day 1 to day 14. repeat Q 3weeks. Four cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators' experimental study found that gossypol was the natural inhibitor of\n      apyrimidinic endonuclease 1 (APE1) and clinical study observed that high expression of APE1\n      was relative to the platinum-resistance in non-small cell lung cancer. Thus the purpose of\n      this study is to find out whether gossypol can improve the sensitivity of cisplatin-based\n      chemotherapy in the  non-small cell lung cancer with apurinic apyrimidinic endonuclease 1\n      (APE1) high expression"
        }, 
        "brief_title": "Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologic or cytologic diagnosis of NSCLC, Stage IIIB/IV.\n\n          -  Males or females between 18 Years to 75 Years.\n\n          -  No prior cisplatin-based chemotherapy, if the surgery or radiotherapy has been\n             administered, the interval is at least above four weeks. The interval for targeted\n             therapy such as EGFR TKI is above 2 weeks.\n\n          -  Performance status of 0, 1 on the ECOG criteria. Expected survival is above three\n             months.\n\n          -  At least one unidimensional measurable lesion meeting Response Evaluation Criteria in\n             Solid Tumors (RECIST. 2000).\n\n          -  Patients can have the brain / meningeal metastasis history, but the metastasis must\n             be treated by operation or radiotherapy), and clinically stable for at least 2\n             months.\n\n          -  Adequate hematologic (neutrophil count >= 1,500/uL, platelets >= 100,000/uL), hepatic\n             (transaminase =< upper normal limit(UNL)x2.5, bilirubin level =< UNLx1.5), and renal\n             (creatinine =< UNL) function.\n\n          -  Patient compliance that allow adequate follow-up. Informed consent from patient or\n             patient's relative.\n\n          -  APE1 IHC (++ or +++).\n\n          -  If female: childbearing potential either terminated by surgery, radiation, or\n             menopause, or attenuated by use of an approved contraceptive method (intrauterine\n             device [IUD], birth control pills, or barrier device) during and for 2 months after\n             trial. If male, use of an approved contraceptive method during the study and 2 months\n             afterwards. Females with childbearing potential must have a urine negative HCG test\n             within 7 days prior to the study enrollment.\n\n          -  No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital,\n             phenytoin, ketoconazole.\n\n        Exclusion Criteria:\n\n          -  Inability to comply with protocol or study procedures.\n\n          -  Medically uncontrolled serious heart, lung, neurological, psychological, metabolic\n             disease.\n\n          -  Second primary malignancy that is clinically detectable at the time of consideration\n             for study enrollment.\n\n          -  Pregnant or breast-feeding.\n\n          -  Enrollment in other study within 30 days.\n\n          -  Brain metastasis with symptoms.\n\n          -  Hypokalemic periodic paralysis history."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "204", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977209", 
            "org_study_id": "GTCA"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "intervention_name": "Gossypol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gossypol acetic acid", 
                "Docetaxel", 
                "Cisplatin", 
                "Gossypol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "NSCLC; Gossypol; APE1; Chemotherapy", 
        "lastchanged_date": "October 30, 2013", 
        "location": [
            {
                "contact": {
                    "email": "dongwang64@hotmail.com", 
                    "last_name": "Dong Wang, PH.D.", 
                    "phone": "86-23-68757151"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "400042"
                    }, 
                    "name": "Daping Hospital, Third Military Medical University"
                }, 
                "investigator": {
                    "last_name": "Dong Wang, PH.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xianquan Zhang, M.D.", 
                    "phone": "86-23-63693000"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing"
                    }, 
                    "name": "The Second Affiliated Hospital of Medical University Of Chongqing"
                }, 
                "investigator": {
                    "last_name": "Xianquan Zhang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Debing Xiang, M.D.", 
                    "phone": "86-13320336639"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing"
                    }, 
                    "name": "Jiangjin Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Debing Xiang, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zhixiang Yang, M.D.", 
                    "phone": "13032372491"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing"
                    }, 
                    "name": "Chongqing Zhongshan Hospital"
                }, 
                "investigator": {
                    "last_name": "Zhixiang Yang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Biyong Ren", 
                    "phone": "13896327099"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing"
                    }, 
                    "name": "Three Gorges Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Biyong Ren, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Qi Zhou, M.D.", 
                    "phone": "86-23-7222676"
                }, 
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing"
                    }, 
                    "name": "Fuling Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Qi Zhou, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression", 
        "overall_contact": {
            "email": "dongwang64@hotmail.com", 
            "last_name": "Dong Wang, PH.D.", 
            "phone": "86-23-68757151"
        }, 
        "overall_official": {
            "affiliation": "Cancer Center, Daping Hospital, Third Military Medical University", 
            "last_name": "Dong Wang, PH.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "the first day of treatment to the date that disease progression is reported; assesed up to 4 years"
        }, 
        "reference": [
            {
                "PMID": "16957145", 
                "citation": "Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983-91."
            }, 
            {
                "PMID": "22122463", 
                "citation": "Kelley MR, Georgiadis MM, Fishel ML. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr Mol Pharmacol. 2012 Jan;5(1):36-53. Review."
            }, 
            {
                "PMID": "19324449", 
                "citation": "Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer. 2009 Dec;66(3):298-304. doi: 10.1016/j.lungcan.2009.02.019. Epub 2009 Mar 25."
            }, 
            {
                "PMID": "22112969", 
                "citation": "Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012 Jul;23(7):1803-8. doi: 10.1093/annonc/mdr555. Epub 2011 Nov 23."
            }, 
            {
                "PMID": "21289522", 
                "citation": "Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, Wood BA, Leopold L. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol. 2011 Apr;6(4):781-5. doi: 10.1097/JTO.0b013e31820a0ea6."
            }, 
            {
                "PMID": "23690416", 
                "citation": "Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul 1;31(19):2404-12. doi: 10.1200/JCO.2012.46.9783. Epub 2013 May 20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977209"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Third Military Medical University", 
            "investigator_full_name": "Dong Wang", 
            "investigator_title": "chief physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "the first day of treatment to death or last survival confirm date; assesed up to 4 years"
            }, 
            {
                "description": "The ratio between the number of responders and number of patients assessable for tumor response", 
                "measure": "Tumor response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.", 
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "the first date of treatment to 30 days after the last dose of study drug"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "the day before every cycle of chemotherapy;  30 days after the last dose of study drug"
            }
        ], 
        "source": "Third Military Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Third Military Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}